| |
 |
 |
 |
 |
 |
 |
 |
June 30, 2004
AnGes MG
to Join the University of Tokyo (Hospital) Project:"22nd
Century Medical Center" (tentative name)
-Establishes joint research program on forefront clinical medicine,
including development of genetic medication and cell remediation
medicines.- |
 |
|
|
AnGes MG hereby officially announces its commitment
to participation in the "22nd Century Medical Center " project
of the University of Tokyo Hospital.
This decision will enable AnGes MG to hold free courses at
the 22nd Century Medical Center, which is scheduled to be inaugurated
in the year 2006 by the University of Tokyo Hospital, to develop
new therapies for cardiovascular disorders_using genetic and
cell remediation medications_and to conduct clinical studies
on new treatments.
AnGes MG is a so-called university spin out venture founded in
1999 when a business entity was needed to market the R&D
fruits from Osaka University Graduate School of Medicine.
The business is based on three seed technologies related to genetic
medicines and efforts are being made now to put them into practical
use and market them through an industrial-academic cooperation
with the Osaka University Graduate School of Medicine. As for
new technologies to be developed in the future, AnGes MG has
been reviewing and assessing the research results of universities
nationwide for their eventual commercialization.
The 22nd Century Medical Center project, which has accepted the
participation of AnGes MG, is a facility to be inaugurated in
the course of fiscal 2006 by the University of Tokyo Hospital
as a future hub for industrial and academic medical research
in Japan. As national universities have been turned into independent
administrative entities by the new law put into effect this year,
research conducted by universities will need to have more commercial
significance in addition to its academic value. Therefore, industry-related
clinical medicine at the 22nd Century Medical Center will also
be the subject of studies and with the commencement of free courses
by private enterprises, the research outcomes of industrial-academic
cooperation will move closer to the commercial end of the spectrum.
AnGes MG has been making progress in the development of new genetic
medicines in the field of cardiovascular and circulatory disorders,
and with its participation in the 22nd Century Medical Center
project, major achievements in cutting-edge therapies are expected.
Cooperation with leading medical entities such as the University
of Tokyo Hospital and the Tokyo University Faculty of Medicine
will also become possible, fueling expectations for the research
of new therapies as genetic and cell remediation therapies in
the field of cardiovascular disorders.
With its participation in the project, AnGes MG hopes to dramatically
increase its opportunities for securing and commercializing new
seed technologies. |
|
|
